{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-282054","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.857236+00:00","generated_at":"2026-06-21T22:20:27.562308+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaccinex reports 100% recurrence-free at 24 months in Stage III melanoma triple combination","bullets":["Triple combo (pepinemab+nivolumab+ipilimumab) achieved 100% recurrence-free survival at 24 months vs <40% for dual combos.","LAG-3 upregulation identified as resistance mechanism to pepinemab+nivolumab; rationale for triple with LAG-3 inhibitor.","Pepinemab combinations induced tertiary lymphoid structures and CD26hi CD4+ T cells in tumors.","Phase 1/2 trial enrolling for pepinemab+trastuzumab+DC vaccine in HER2+ metastatic breast cancer (NCT05378464).","Interim analysis of KEYNOTE-B84 (pepinemab+KEYTRUDA in HNSCC) expected in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-282054","json":"https://secwatch.observer/filing/0001193125-22-282054.json","markdown":"https://secwatch.observer/filing/0001193125-22-282054.md","text":"https://secwatch.observer/filing/0001193125-22-282054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522282054/0001193125-22-282054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522282054/d408251d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:20:27.562308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}